MarketLens
Sign Up

Kymera's High-Flying Stock Meets Insider Selling

3 months ago
SHARE THIS ON:

Kymera's High-Flying Stock Meets Insider Selling

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?

Kymera Therapeutics advanced its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition. No financial terms or timelines were...
Stock News•1 months ago

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

Keros Therapeutics authorized a $5 million share repurchase program after receiving a $20 million development milestone from Takeda, triggered by first-patient dosing in the ELRiSE MDS trial. The buyb...
Stock News•3 months ago

Kymera's CEO Sold $6 Million in Stock After a 170% Run

Kymera CEO sold ~$6M in stock after a 170% run, exercising 50,000 shares at $119 on July 7. The sale reduced direct holdings by 7%.

Breaking News

View All →

Top Headlines

View More →
Stock News•3 hours ago

Prediction: Nvidia Stock Is Going to Soar After Nov. 17

Stock News•6 hours ago

1 Reason to Buy Microsoft Stock for 10 Years

Stock News•7 hours ago

Lumentum Earnings Preview: The AI Boom Is Already Priced In

Stock News•7 hours ago

Rivian Earnings Don’t Mask Stock Collapse

Stock News•7 hours ago

History Says Now Is the Perfect Time to Buy Nvidia Stock